Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia.
Ballantyne CM, Vasas S, Azizad M, Clifton P, Rosenson RS, Chang T, Melquist S, Zhou R, Mushin M, Leeper NJ, Hellawell J, Gaudet D.
Ballantyne CM, et al. Among authors: zhou r.
N Engl J Med. 2024 May 28. doi: 10.1056/NEJMoa2404143. Online ahead of print.
N Engl J Med. 2024.
PMID: 38804517